Nuformix plc (LON:NFX – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as GBX 0.18 ($0.00) and last traded at GBX 0.18 ($0.00), with a volume of 1347616 shares traded. The stock had previously closed at GBX 0.21 ($0.00).
Nuformix Stock Performance
The firm has a market capitalization of £1.50 million, a P/E ratio of -1.63 and a beta of 0.29. The stock has a 50-day moving average of GBX 0.22 and a 200 day moving average of GBX 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.51.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Nuformix
- What Are Growth Stocks and Investing in Them
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Where Do I Find 52-Week Highs and Lows?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Energy and Oil Stocks Explained
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
